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Abstract
Molecular plant components have long been aimed at the angiogenesis and anti-angiogenesis pathways, and have been 
tested as sources for antineoplasic drugs with promising success. The present work deals with the  anti-angiogenic 
effects of Methyl Jasmonate. Jasmonate derivatives were demonstrated to selectively damage the mitochondria of 
cancer cells. In vitro, 1-10 mM Methyl Jasmonate induced the cell death of the human umbilical vein endothelial 
cells (HUVEC) and the Murine melanoma cells (B16F10), while micromolar concentrations were ineffective. In vivo, 
comparable concentrations were toxic and reduced the vessel density of the Chorioallantoic Membrane of the Chicken 
Embryo (CAM). However, 1-10 µM concentrations produced a complex effect. There was increased  capillary budding, 
but the new vessels were leakier and less organised than corresponding controls. It is suggested that not only direct 
toxicity, but also the drug effects upon angiogenesis are relevant to the antineoplasic effects of Methyl Jasmonate.
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Efeitos antiangiogênicos in vivo convalidam a atividade  
antineoplásica potencial do metiljasmonato
Resumo
Moléculas de origem vegetal são, há muito, conhecidas como substâncias ativas sobre as vias de angiogênese e an-
tiangiogênese e foram testadas como fonte de drogas antineoplásicas com sucesso promissor. Este trabalho trata dos 
efeitos antiangiogênicos do Metiljasmonato, um protótipo da família dos derivados do ácido jasmônico, que danifi-
cam seletivamente a mitocôndria de células neoplásicas. In vitro, metiljasmonato 1-10 mM promoveu a morte celular 
de células endoteliais humanas de cordão umbilical (HUVEC) e de melanoma murino (B16F10); concentrações 
micromolares foram inócuas. In vivo, concentrações equivalentes foram tóxicas e reduziram a densidade de vasos 
em membranas corioalantoicas de embrião de galinha (CAM). Entretanto, concentrações entre 1-10 µM produziram 
um efeito complexo. Ocorreu aumento no brotamento capilar, mas os novos vasos apresentaram-se frágeis e menos 
organizados que os controles correspondentes. Sugere-se que, além da toxicidade direta contra as células tumorais, a 
ação do metiljasmonato sobre a angiogênese seja relevante para seu efeito antineoplásico.
Palavras-chave: metiljasmonato, antiangiogênese, modelo da CAM, cultura de células endoteliais, HUVEC.
1. Introduction
Jasmonate derivatives are recognised as cytotoxic 
substances against tumor cells that induce apoptosis in 
malignant cells through different pathways, while the 
corresponding normal cell types were resistant, high-
lighting the therapeutic potential of these molecules as 
antineoplasic substances.(Fingrut and Flescher, 2002). 
The mitochondrial membrane is the likely target for the 
p53-independent Jasmonates cytotoxicity (Rotem et al., 
2005). Other targets were considered, taking into account 
the structural similarities between Jasmonate derivatives 
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and prostaglandins (Conti et al., 2007). Remarkably, 
endothelial cell lineages have never been tested for 
Jasmonates toxicity, despite its known susceptibility to 
apoptosis. Endothelial and tumor cells share mitochon-
drial structural and functional peculiarities that prompt-
ed us to hypothesise that both cell types could present 
analogous susceptibility to Jasmonates. Indeed, both 
cell types present anaerobic metabolism dependence 
(Gatenby, R.A.; Gillies, 2004) and higher mitochondrial 
heterogeneity than most of the other cell types (Collins 
et al., 2002; De Giorgi et al., 2000). Indeed, Methyl 
Jasmonate was now found to be an anti-angiogenic 
compound both in Endothelial Cell cultures in vitro 
and in the model of angiogenesis in Chicken Embryo 
Chorioallantoic Membrane in vivo. Altogether, the well-
known cytotoxicity of Methyl Jasmonate against cancer 
cells and its in vivo anti-angiogenic action, adjudicate its 
use for therapeutic purposes.
2. Materials and Methods
2.1. Preparation of methyl jasmonate
The commercial methyl (1R, 2R)-3-Oxo-2-(2Z)-2-
pentenyl-cyclopentanoacetate (Methyl dihydrojasmonate 
96% cis-trans mixture Sigma Aldrich - Missouri - USA) 
was diluted in absolute ethanol (Merck). It was analysed 
by gas chromatography mass spectrometry (GC-MS) 
in a Focus chromatograph coupled to a PolarisQ mass 
spectrometer equipped with automatic injector and ion 
trap TriPlus, as described (Mueller et al., 2006). Samples 
(1 μL) were splitless mode injected at 250 °C, under 
0.6 mL/min He flow. Each chromatogram was initiated 
at 100 °C, for 1 minute, and then the temperature was 
increased 10 °C/min until 300 °C, and kept constant for 
4 minutes. Transfer line and detector were at 250 and 
200 °C, respectively. Full scan - m/z: 50-400 Mass spec-
trum was obtained and compared with the literature 
(Schmelz et al., 2003, Mueller et al., 2006). The com-
pound was employed either purely or dissolved in etha-
nol for all the biological assays.
2.2. In vitro toxicity and endothelial cell cultures 
Human umbilical cord vein endothelial cells (HUVEC) 
were grown 5 × 104 cells/mL in RPMI 1640 containing 
10% fetal calf serum in 96 wells plates. Adherence was 
obtained after 3-6 hours at 37 °C/5% CO2. The MTT test 
was performed as described (Denizot and Lang, 1986, 
modified). Briefly, adhered cells were exposed to Methyl 
Jasmonate in serum free RPMI for 24 hours. After this 
time, the medium was removed through soaking and then 
each well was added with 50 μL of MTT (1 mg.mL–1) 
in phenol red free RPMI. The plates were shaken for 
3 hours and the medium was removed by inversion. MTT 
Formazan was dissolved through swirling with 100 μL 
of DMSO for 30 minutes and measured in a spectro-
photometric ELISA reader at 580 nm. Controls were 
processed as samples, excluding the Methyl Jasmonate. 
Growth curves were followed for 96 hours after adhered 
cells were exposed to Methyl Jasmonate in RPMI 1640 
containing 10% fetal calf serum. After trypsinization and 
quantitative suspension of each individual well content 
in an isotonic solution of Trypan Blue, viable cells were 
counted twice in a 0.4 mm3, using a Neubauer chamber. 
Individual data points were obtained as a mean of inde-
pendent triplicates, at 24 hours intervals. VEGF produc-
tion was analysed in the cell culture supernatants after 
4 hours exposition to known concentrations of Methyl 
Jasmonate with the commercial ELISA kit (R&D 
System, Minneapolis, Mn, USA, cat n. DY293B). Cell 
death was evaluated by cell cycle analyses performed us-
ing Flow Cytometry (FACScalibur, BD, USA). In this 
case cells were used after 18 hours exposition and incu-
bation with propidium iodide. To estimate the possible 
involvement of cell death versus autophagy, cells were 
incubated with Acridine Orange and analysed by Flow 
Cytometry as well (Klionsky et al., 2008). 
2.3. In vivo angiogenesis assay (CAM model)
The effect of Methyl Jasmonate on angiogenesis was 
studied in the incubated eggs lying on a hatching tray, as 
described (Ribatti et al., 1996; 2000). Recent 24 hours 
postured eggs of 18 m old Gallus Domesticus, white 
and weighing approximately 45 g, were incubated in a 
brooder (Zagas - São Paulo-SP) at 51% internal humid-
ity and 37.2 °C. After 5 days of incubation, the eggs were 
taken to a lamellar flow camera and 5 mL of albumin 
were removed through a small hole produced in the air 
chamber, with a 27 × 5 mm disposable needle coupled 
to a 5 mL sterile syringe. The left needle’s hole, at the 
external egg shell air chamber, was sealed with a piece of 
sterile tape. After this procedure, a piece of approximate-
ly 2 cm2 of the egg shell was carefully removed in order 
to provide an observation window in the upper face of 
the egg. After confirmation of the existence and viability 
of the embryo, the window was sealed with transparent 
sterile tape, avoiding external contact. Incubation was 
continued for another 120 hours, and was inspected each 
day with the development and viability of the embryo. At 
the end of this period, the tape was again opened at the 
lamellar flow camera and a circular filter, sterile, 5 mm 
in diameter was deposited on the outside of the yolk sac. 
This filter serves as a support for the application of dif-
ferent doses of Methyl Jasmonate. The collection of the 
material occurred after the euthanasia of the embryo by 
hypothermia and further fixation with the use of formalin 
for a 20 minutes period. The CAM was then cut around 
the disc or the site of application and washed with phos-
phate-buffered saline isosmotic ice, placed, well dis-
tended, between slide and coverslip and photographed 
with the programme ACT-2U by a digital DS-U1 camera 
attached to a stereoscopic Nikon SMZ1800 microscope 
at 2× magnification, standardised illumination, shadow 
regulation and TIFF image resolution. The images were 
analysed for vessel densities with the programme Image 
J. Results were expressed in the number of pixels of the 
images obtained after preset threshold binary conversion 
(Areas).
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3. Results
MeJa consistently impaired vascular growth in this 
Chorioallantoic model of angiogenesis, but its effects 
seemed to occur through at least two different mecha-
nisms depending on the applied dosage. Lower concen-
trations typically (<100 μM MeJa) resulted in disordered 
vascular growth, forming lots of capillary anastomosis 
and dysfunctional vessels, compatible with VEGF with-
drawing. On the other hand, milimolar concentrations 
significantly reduced the capillary growth, an effect 
which is most likely associated with direct cytotoxic-
ity. (Figure 1). In order to better understand the in vivo 
observed effect, cell culture effects were characterised. 
Both the classical endothelial cell lineage, HUVEC, and a 
MeJa susceptible neoplasic cell lineage, B16F10 murine 
melanoma, were studied. Melanoma cells and HUVECs 
presented similar susceptibility to MeJa cytotoxical ef-
fects in the MTT test (Figure 2). Toxic concentrations 
were in the 1-10 mM range for both cells. Less confluent 
cultures exposed to 1-10 μM MeJa consistently produced 
higher MTT reduction than corresponding controls (not 
shown). However, growth curves failed to demonstrate 
increased cell proliferation, despite cytotoxicity being 
unequivocally shown at 1-10 mM MeJa (Figure 2). 
Flow Cytometry studies confirmed apoptotic cell 
death of HUVECs with 10 mM MeJa, while 1 mM MeJa 
induced cell cycle G1 arrest, as shown in (Table 1). In en-
dothelial cells and at micromolar concentrations, MeJa 
also induced early effects such as morphological chang-
es (multinucleation, microvacuolation, cell shrinkage 
and apoptotic bodies), and metabolic changes, revealed 
through combined Acridine Orange/Propidium Iodide 
probing and decreased VEGF production (Table 1).
Figure 1. Typical aspects of the MeJa in vivo effects upon the angiogenesis within the Chicken Embryo Chorioallantoic 
Membrane. Unexposed control and log-based series of MeJa exposed membranes as exemplified, with the corresponding 
concentration in the upper corner of each image. Lower right panel shows the measured mean ± standard deviation vessel 
areas for independent samples, (n ≥ 3), measured after binarization of the digital images as described in Materials and Meth-
ods. Results were plotted as pixel densities in relation to molar concentrations of MeJa, in a linear × log format. Image size: 
1280 × 960 pixels. Optical magnification: 2×.
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4. Discussion
Our results demonstrated, for the first time to our 
knowledge, the influence of MeJa in angiogenic devel-
opment in vivo, demonstrating its potential as a thera-
peutic option for cancer treatment. 
It should be noted that the functional proximity 
among MeJa and cyclopentenone prostaglandins has 
been addressed by Conti (Conti, 2006). These com-
pounds share with MeJa the ability to induce cancer 
cell cycle G1 arrest at concentrations slightly lower than 
those employed to promote overt cell death (Hsiang and 
Straus, 2002). Also, the 2-cyclopentenone ring itself was 
reported to be pro-apoptotic to HUVECs at concentra-
tions as low as 0.25 μM (Vosseler and Weber, 2003). 
Indeed, the cell cycle G1 arrest and death induction 
of normal endothelial cells from the HUVEC lineage as 
reported in Table 1, also leads us to consider similar tar-
gets, despite MeJa lack of the minimal cyclopentenone 
structure (Vosseler and Weber, 2003). The putative cyto-
toxicity mechanisms of the cyclopentenone prostagland-
ins are NFκB activation blockage and PPARγ activation 
(Bishop-Bailey and Hla, 1999; Straus et al, 2000; Rossi 
et al., 2000). Both pathways are known to be relevant 
for the control of vascular growth and differentiation 
in vivo, as the transcription signals promote VEGF and 
other growth factors expression. In miofibroblasts, the 
activation of the peroxisome proliferator-activated recep-
tor (PPAR)-γ by its agonists induces VEGF expression 
while simultaneously decreasing inflammation (NF-KB) 
(Chintalgattu et al., 2007). VEGFR2 expression is an ad-
ditional target of PPAR activation in endothelial cells. 
In HUVECs, an anti-angiogenic effect was reported for 
Figure 2. MeJa citotoxicity for HUVEC (□■, left panels) and B16F10 (○●right panels) cells measured through MTT re-
duction test, after 24 hours exposition (open symbols) or expressed as log phase doubling times, in 5 days cultures (closed 
symbols).
Table 1. Cell Cycle and metabolic effects of MeJa upon HUVEC cells.
Cell cycle profile, 18 hours Acridine orange 
labelled cells (%)
VEGF (pg/mL) 
2 × 106 cells, 4 hoursDead cells (%) G0/G1 (%) G2/S (%)
Untreated 6 59 35 6.3 ± 0,1 431 ± 67
10 mM 93 5 2 n.d.a n.d.a
1 mM 13 72 15 6.2 ± 0.1 566 ± 31
100 μM 8 56 36 6.7± 0.3 450 ± 30
10 μM 7 60 33 9.0 ± 0.5 319 ± 12b
a
 n.d. – not determined. Data point interpretation precluded due to extensive cell death. (n = 3); b (Control × 10 μM treated, 
p < 0.05).
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PGJ2, a PPAR agonist which simultaneously produces a 
moderate VEGF increase and a transient and self-limited 
VEGFR2 decrease (Funovics et al., 2006). It is important 
to mention that these mechanisms synergise, but are not 
necessarily interdependent. On the other hand, the mito-
chondria proved to be the main target to MeJa induced 
cell death (Rotem et al., 2005; Goldin et al., 2007). 
Nonetheless, despite HUVECs and B16F10 melanoma 
cells presenting similar susceptibility to the toxic mili-
molar doses of MeJa, as both cell types were unaffect-
ed by lower MeJa doses (Figure 2), VEGF production 
showed a discrete 20% increase at 4 hours exposition 
(Table 1) and this probably represents an early and tran-
sient survival signal. 
It is speculated if VEGF increases and VEGFR2 
transient decreases, they could play a role in vascular 
leakiness. Vascular permeability is controlled by VEGF 
and angiopoietins which bind to a tyrosine kinase recep-
tor. Increased VEGF promotes receptor cleavage and in-
hibits vascular stabilisation mediated by angiopoietin-1 
(Thurston et al, 1999; Findley et al., 2007). On the other 
hand, VEGF withdrawn in the presence of Angiopoietin-2 
results in low vessel maturation, increased proliferation 
and leakiness. 
In accordance with previously reported effects of the 
cyclopentenone prostaglandins (Funovics et al., 2006), 
in vivo effects were surprisingly intense, not only at the 
toxic milimolar doses, but also in micromolar concentra-
tion ranges. Convergent, but distinct, effects were seen 
in milimolar and micromolar concentrations of MeJa. 
Higher doses impacted vessel growth, resulting in lower 
densities, probably after gross energy metabolism impair-
ment and increased cell death (Figure 1) following the 
transient stimulation of VEGF production. On the other 
hand, an in vivo increased and disordered proliferation 
associated to dysfunctional vessels in the CAMs exposed 
to lower doses (Figure 1). This effect is probably depend-
ent on more complex signal transduction. We could not 
find important cell cycle effects upon HUVEC cells in 
this concentration range, except for a discrete increase 
of the Acridine Orange labelling at 10 μM (Table 1), 
which may indicate one attempt of the cells to survive by 
stimulation of some autophagy. Conversely, with the in-
crease in concentration, autophagy would not be present 
and apoptotic cell death would occur. Redox imbalance 
are surely involved in the cell senescence mechanism 
(Muller, 2009), however the results presented in Table 1 
only allow us to consider senescence induction among 
the possibilities of MeJa cytotoxicity towards endothe-
lial cells at milimolar, but not at micromolar concentra-
tion range.
Decreased in vitro VEGF production was observed 
at micromolar doses, which is compatible with the pat-
tern of vascular impairment observed in vivo. Similar ef-
fects of VEGF withdrawn were described in tumors and 
in the uterine epithelium (Benjamin and Keshet, 1997, 
Matsumoto et al., 2002). VEGF withdrawn effects of 
MeJa can derive from the suppression of COX-2 tran-
scription through either AP-1 dependent and independ-
ent mechanisms (Subbaramaiah et al., 2001). Several of 
the known anti-neoplastic properties of PGJ2 and PPARγ 
ligands rely on their ability to inhibit COX-2 expression 
and PG biosynthesis (Simmons et al., 2004). COX-2 inhi-
bition is particularly impor tant in the neoplastic, as well 
as in the embryonic, microenvironment. COX-2 expres-
sion is driven by shear stress and hypoxia and is much 
less relevant in normal than in rapid growing and in-
flamed or regenerating tissues (Greenhough et al., 2009). 
The COX-2/PGE2 pathway has multiple pro-angiogenic 
effects. PGE2 can enhance the hypoxia induced factor-
dependent expression of VEGF-A, and also the expres-
sion of other VEGFs and chemokine receptors acting 
upon microvessel assembly (Su et al., 2004; Pan et al., 
2008). The COX-2 expression and the consequent PGE2 
production are higher in the migrating cells of develop-
ing sprouts than in the confluent endothelial monolayer 
of mature vessels. In the actively growing tumor vessels, 
PGE2 acts as an autocrine signal for vascular sprouting 
(Jiang et al., 2004). The inhibition of the COX-2/PGE2 
pathway is therefore expected to constrain the produc-
tion of functional neovessels inside tumors. Moreover, 
there are other relevant mechanisms implied in vascula-
ture impairment and leakage. Some of them can only be 
disclosed in complex models and not in the monotype 
cell cultures, as they stand for the endothelial cells, peri-
cytes, and smooth muscle cells interactions (Lee et al., 
2006). PGJ2 was reported to promote adipose conversion 
in a variety of cell lines, to block myogenesis through 
inhibition of Myo D gene expression, and to induce the 
PPARγ angiopoietin related (PGAR) protein expression 
in endothelial cells (Hu et al., 1995, Hunter et al., 2001, 
Salcedo et al., 2003). This close angiopoietin-2 related 
protein is particularly present in placental tissues and 
accounts for vascular remodelling (Yoon et al., 2000). 
Whichever mechanism predominates in vivo, it is pro-
posed that MeJa can make the neovessels so leaky as to 
cause tumor destruction.
Critical imbalance effects of a myriad of pro- and 
anti-angiogenic growth factors were obviously fa-
voured within the extra-embryonic egg tissue model. 
Outstandingly, presented results disclose the synergistic 
and multitargeted actions of MeJa. In conclusion, mech-
anistic insight was provided through paired endothelial 
cell cultures and in vivo assays. The converging in vivo 
anti-angiogenic actions adds to the promising therapeu-
tic application of Methyl Jasmonate as an antineoplasic 
substance. 
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